Drug
Ziresovir clinical trials
Also written AK0529.
- studies test it
- 12
- open now
- 2
- in phase 3
- 3
- first study started
- 2014
Keep track of what changes. Save the ziresovir studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
12 studies that test it; most in 2024 (2)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2023 | 1 |
| 2024 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 6
- Phase 2
- 4
- Phase 3
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 12 · Other 0
Shanghai Ark Biopharmaceutical Co., Ltd. (12)
Studies
Open first, then newest update. How each study uses ziresovir is read from its arms, and is right about nine times in ten.
Testing it · 12
- A Study of Ziresovir (AK0529) in High-risk Adult With Respiratory Syncytial Virus (RSV) Infection.RecruitingPhase 2/3Shanghai Ark Biopharmaceutical Co., Ltd.NCT07658534Written as Ziresovir (AK0529)
- A Study to Confirm the Effectiveness and Safety of AK0529 in Treating RSV Infections in Hospitalized InfantsRecruitingPhase 3Shanghai Ark Biopharmaceutical Co., Ltd.NCT06775405Written as AK0529
- Thorough QT/QTc (TQT) Clinical Study to Evaluate the Effects of Ziresovir on Cardiac Repolarization in Healthy SubjectsCompletedPhase 1Shanghai Ark Biopharmaceutical Co., Ltd.NCT06591845Written as Ziresovir 125 mg
- Anti-RSV Study in Chinese Patients (ASCENT)TerminatedPhase 2Shanghai Ark Biopharmaceutical Co., Ltd.NCT03699202Written as AK0529
- A Study of AK0529 in Adults Patients Hospitalized With RSV InfectionCompletedPhase 2Shanghai Ark Biopharmaceutical Co., Ltd.NCT06942299Written as AK0529
- Viral Inhibition in Children for Treatment of RSVCompletedPhase 2Shanghai Ark Biopharmaceutical Co., Ltd.NCT02654171Written as AK0529
- A Study of AK0529 in Chinese Infants Hospitalized With RSVCompletedPhase 3Shanghai Ark Biopharmaceutical Co., Ltd.NCT04231968Written as AK0529
- A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Ziresovir in Healthy SubjectsCompletedPhase 1Shanghai Ark Biopharmaceutical Co., Ltd.NCT04788017Written as Ziresovir
- A Study of AK0529 to Evaluate Pharmacokinetics and Safety in Chinese Healthy VolunteersCompletedPhase 1Shanghai Ark Biopharmaceutical Co., Ltd.NCT03322800Written as AK0529
- A Study to Evaluate the Pharmacokinetics, Metabolism, and Excretion of AK0529CompletedPhase 1Shanghai Ark Biopharmaceutical Co., Ltd.NCT03400995Written as AK0529
- A Study of AK0529 in Infants Hospitalized With RSVTerminatedPhase 1Shanghai Ark Biopharmaceutical Co., Ltd.NCT02460016Written as AK0529
- Safety, Tolerability and PK Study of AK0529 in Healthy HumanCompletedPhase 1Shanghai Ark Biopharmaceutical Co., Ltd.NCT02297594Written as AK0529
Codes
What other systems call ziresovir · ClinicalTrials.gg INT001344
- MeSH (NLM) C000707852ziresovirConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) XCF42D7AG4ZIRESOVIRConfirmed FDA, NLM
- NCI Thesaurus C170395ZiresovirOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000707852 | ziresovir | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | XCF42D7AG4 | ZIRESOVIR | Confirmed FDA, NLM |
| NCI Thesaurus | C170395 | Ziresovir | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.